ATE440089T1 - Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen - Google Patents
Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onenInfo
- Publication number
- ATE440089T1 ATE440089T1 AT03700408T AT03700408T ATE440089T1 AT E440089 T1 ATE440089 T1 AT E440089T1 AT 03700408 T AT03700408 T AT 03700408T AT 03700408 T AT03700408 T AT 03700408T AT E440089 T1 ATE440089 T1 AT E440089T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- side chain
- oligomers
- amino acid
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Polyamides (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0004194A KR100464261B1 (ko) | 2002-01-24 | 2002-01-24 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
PCT/IB2003/000164 WO2003062212A1 (en) | 2002-01-24 | 2003-01-23 | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE440089T1 true ATE440089T1 (de) | 2009-09-15 |
Family
ID=27607011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03700408T ATE440089T1 (de) | 2002-01-24 | 2003-01-23 | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen |
Country Status (9)
Country | Link |
---|---|
US (1) | US7022851B2 (de) |
EP (1) | EP1470114B1 (de) |
JP (1) | JP4394952B2 (de) |
KR (1) | KR100464261B1 (de) |
CN (1) | CN100351243C (de) |
AT (1) | ATE440089T1 (de) |
DE (1) | DE60328866D1 (de) |
DK (1) | DK1470114T3 (de) |
WO (1) | WO2003062212A1 (de) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100464264B1 (ko) * | 2002-03-21 | 2005-01-03 | 주식회사 파나진 | 광분해 보호기를 갖는 신규한 pna 단량체 |
KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
WO2005084672A1 (de) * | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
AU2006252346B2 (en) | 2005-06-02 | 2012-06-28 | Advandx, Inc. | Peptide nucleic acid probes for analysis of microorganisms |
KR101072899B1 (ko) | 2008-01-21 | 2011-10-17 | 주식회사 파나진 | 아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용 |
WO2009136693A1 (en) * | 2008-05-06 | 2009-11-12 | Panagene Inc. | Peptide nucleic acid probes, kits and methods for expression profiling of micrornas |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
JP5875976B2 (ja) | 2009-06-01 | 2016-03-02 | ヘイロー−バイオ アールエヌエーアイ セラピューティクス, インコーポレイテッド | 多価rna干渉のためのポリヌクレオチド、組成物およびそれらの使用方法 |
AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
WO2011064552A1 (en) | 2009-11-30 | 2011-06-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
WO2011113015A2 (en) | 2010-03-12 | 2011-09-15 | Avi Biopharma, Inc. | Antisense modulation of nuclear hormone receptors |
JP6066900B2 (ja) | 2010-04-26 | 2017-01-25 | エータイアー ファーマ, インコーポレイテッド | システイニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
AU2011248614B2 (en) | 2010-04-27 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
JP6008840B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | フェニルアラニルαtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CN103140233B (zh) | 2010-05-03 | 2017-04-05 | Atyr 医药公司 | 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
WO2011139986A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
AU2011248101B2 (en) | 2010-05-04 | 2016-10-20 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
CA3090304A1 (en) | 2010-05-13 | 2011-11-17 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
EP2568996B1 (de) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen |
JP6027965B2 (ja) | 2010-05-17 | 2016-11-16 | エータイアー ファーマ, インコーポレイテッド | ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
EP2575856B1 (de) | 2010-05-27 | 2017-08-16 | aTyr Pharma, Inc. | Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
EP2611791A4 (de) | 2010-08-12 | 2014-02-12 | Univ New York | Oligooxopiperazine sowie verfahren zu ihrer herstellung und verwendung |
EP2608801B1 (de) | 2010-08-25 | 2019-08-21 | aTyr Pharma, Inc. | Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen |
AU2012284259A1 (en) | 2011-07-15 | 2014-03-06 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
KR101303699B1 (ko) | 2011-07-20 | 2013-09-09 | 대한민국 | Pna 칩을 이용한 다종 식중독균 검출 방법 |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
WO2013086441A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
CN105246481A (zh) | 2013-01-19 | 2016-01-13 | 纽约大学 | 用于p53再活化的低聚氧代哌嗪 |
CN111235149B (zh) | 2013-09-05 | 2024-04-16 | 萨罗塔治疗公司(美国) | 酸性α-葡糖苷酶中反义诱导的外显子2纳入 |
KR101830700B1 (ko) | 2013-11-11 | 2018-02-21 | 주식회사 파나진 | 클램핑 프로브 및 검출 프로브를 이용한 다중 표적핵산 검출방법 |
US11180481B2 (en) | 2014-04-15 | 2021-11-23 | New York University | Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction |
KR101951172B1 (ko) | 2014-11-07 | 2019-02-22 | 주식회사 파나진 | 인유두종바이러스의 유전자형 검출을 위한 ρνα 프로브, 키트 및 방법 |
US10517898B2 (en) | 2014-11-20 | 2019-12-31 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
EP3851531A1 (de) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induzierte exonexklusion in typ-vii-kollagen |
JP2018525037A (ja) | 2015-08-24 | 2018-09-06 | ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド | 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用 |
US20190177723A1 (en) | 2015-10-09 | 2019-06-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
EP3411480A4 (de) | 2016-02-02 | 2020-01-22 | Olix Pharmaceuticals, Inc. | Behandlung von atopischer dermatitis und asthma mit auf ll4r , trpa1 oder f2rl1 abzielenden rna-komplexen |
SG11201808964PA (en) | 2016-04-18 | 2018-11-29 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス, インコーポレイテッド | ヒトlmnaを標的にするオリゴヌクレオチド類縁体 |
BR112019000006A2 (pt) | 2016-06-30 | 2019-04-16 | Sarepta Therapeutics, Inc. | oligômeros de salto do exon para distrofia muscular |
WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
WO2018053142A2 (en) | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
MX2019006882A (es) | 2016-12-19 | 2019-08-16 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
LT3554552T (lt) | 2016-12-19 | 2022-10-10 | Sarepta Therapeutics, Inc. | Egzoną praleidžiantys oligomerų konjugatai nuo raumenų distrofijos |
SG10202100491QA (en) | 2016-12-19 | 2021-02-25 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
JP2020517638A (ja) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ, インコーポレイテッド | 肺の炎症を治療するための組成物および方法 |
WO2018218250A2 (en) | 2017-05-26 | 2018-11-29 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
US10421728B2 (en) | 2017-06-08 | 2019-09-24 | Amrita Vishwa Vidyapeetham | Peptide nucleic acid monomer and a preparation method |
EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
EP3687519A1 (de) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Kombinationstherapien zur behandlung von muskeldystrophie |
EP3687547A1 (de) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Kombinationstherapien zur behandlung von muskeldystrophie |
WO2019067981A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
EP3697910A4 (de) | 2017-10-18 | 2021-07-14 | Sarepta Therapeutics, Inc. | Antisense-oligomer-verbindungen |
US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
EP4219717A3 (de) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
US11273137B2 (en) | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
WO2020123574A1 (en) | 2018-12-13 | 2020-06-18 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
CA3132199A1 (en) | 2019-03-12 | 2020-09-17 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
US20220193246A1 (en) | 2019-04-18 | 2022-06-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
US20220226269A1 (en) | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
AU2021232598A1 (en) | 2020-03-04 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
EP4157264A4 (de) | 2020-05-27 | 2024-06-19 | The Regents of the University of California | Zusammensetzungen und verfahren zur transdifferenzierung von zellen |
WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
CA3195231A1 (en) | 2020-09-16 | 2022-03-24 | President And Fellows Of Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
AU2022358322A1 (en) | 2021-09-30 | 2024-05-16 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2023091704A1 (en) | 2021-11-18 | 2023-05-25 | Circularis Biotechnologies, Inc. | Compositions and methods for production of circular nucleic acid molecules |
WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
US20240182561A1 (en) | 2022-11-04 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
WO2024104914A1 (en) | 2022-11-14 | 2024-05-23 | BioNTech SE | Rna capping efficiency assay |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4204870A (en) | 1978-07-25 | 1980-05-27 | Eastman Kodak Company | Photographic products and processes employing novel nondiffusible heterocyclyazonaphthol dye-releasing compounds |
DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
AU646966B2 (en) * | 1991-08-23 | 1994-03-10 | Takeda Chemical Industries Ltd. | 2-piperazinone compounds, their production and use |
US6133444A (en) | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
US5539083A (en) * | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
WO1996040709A1 (en) | 1995-06-07 | 1996-12-19 | Perseptive Biosystems, Inc. | Pna-dna chimeras and pna synthons for their preparation |
DE19620170A1 (de) * | 1996-05-20 | 1997-11-27 | Wolfgang Prof Dr Dr Pfleiderer | Nucleosid-Derivate mit photolabilen Schutzgruppen |
AUPO008396A0 (en) * | 1996-05-27 | 1996-06-20 | Fujisawa Pharmaceutical Co., Ltd. | New piperazine compounds |
AU2298899A (en) * | 1998-02-05 | 1999-08-23 | Takeda Chemical Industries Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
WO2000002899A1 (en) | 1998-07-09 | 2000-01-20 | Biocept, Inc. | Method of using an improved peptide nucleic acid universal library to optimize dna sequence hybridation |
KR20030009903A (ko) * | 2001-07-24 | 2003-02-05 | 삼성정밀화학 주식회사 | 주쇄 2-아미노에틸글리신의 1차 아미노기가p-니트로페닐설포닐에톡시카르보닐기로 보호된 펩타이드핵산 단량체의 제조방법 |
KR20030042180A (ko) * | 2001-11-21 | 2003-05-28 | 주식회사 파나진 | 펩타이드 핵산의 골격을 제조하는 방법 |
KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Pna 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
-
2002
- 2002-01-24 KR KR10-2002-0004194A patent/KR100464261B1/ko active IP Right Grant
-
2003
- 2003-01-23 DK DK03700408T patent/DK1470114T3/da active
- 2003-01-23 CN CNB038064944A patent/CN100351243C/zh not_active Expired - Lifetime
- 2003-01-23 JP JP2003562092A patent/JP4394952B2/ja not_active Expired - Lifetime
- 2003-01-23 EP EP03700408A patent/EP1470114B1/de not_active Expired - Lifetime
- 2003-01-23 WO PCT/IB2003/000164 patent/WO2003062212A1/en active Application Filing
- 2003-01-23 AT AT03700408T patent/ATE440089T1/de not_active IP Right Cessation
- 2003-01-23 DE DE60328866T patent/DE60328866D1/de not_active Expired - Lifetime
- 2003-01-24 US US10/351,173 patent/US7022851B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1470114B1 (de) | 2009-08-19 |
CN1642923A (zh) | 2005-07-20 |
KR100464261B1 (ko) | 2005-01-03 |
EP1470114A4 (de) | 2005-05-11 |
KR20030063848A (ko) | 2003-07-31 |
EP1470114A1 (de) | 2004-10-27 |
CN100351243C (zh) | 2007-11-28 |
US20030195332A1 (en) | 2003-10-16 |
US7022851B2 (en) | 2006-04-04 |
DE60328866D1 (de) | 2009-10-01 |
JP4394952B2 (ja) | 2010-01-06 |
JP2005538928A (ja) | 2005-12-22 |
WO2003062212A1 (en) | 2003-07-31 |
DK1470114T3 (da) | 2009-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE440089T1 (de) | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen | |
ATE447569T1 (de) | Pna-monomer und vorstufe | |
DK2174936T3 (da) | Pna-monomer og prækursor | |
NO20062267L (no) | Hepatitt C virus inhibitorer | |
NO20044807L (no) | Heratitt C virus inhibitorer | |
NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
DK1501507T3 (da) | Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet | |
YU57603A (sh) | Inhibitori fosfodiesteraze 4 | |
NO20062185L (no) | Hepatitt C virus-inhibitorer | |
EA200400886A1 (ru) | Макроциклические пептиды, обладающие активностью в отношении вируса гепатита c | |
WO2005061458A3 (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
WO2002048157A3 (en) | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors | |
CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
NO20050871L (no) | 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer | |
BR0007890A (pt) | Compostos de uracila e uso dos mesmos | |
CA2307824A1 (en) | Processes for producing 7-isoindolinequinolonecarboxylic acid derivatives and intermediates therefor,salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and compositions containing the same as active ingredient. | |
DK1706414T3 (da) | Fremgangsmåde til fluorcytidinderivater | |
DK1644389T3 (da) | Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger | |
EA200400690A1 (ru) | Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз | |
NO20033129L (no) | Anvendelse av 2-amino-tiazolinderivater som inhibitorer for induktibel NO-syntase | |
ATE412628T1 (de) | N- (1-dimethylaminocycloalkyl)methyl benzamid- derivate | |
DE60125053D1 (de) | Cephem verbindungen und diese enthaltende esbl nachweisreagenzien | |
EA200200807A1 (ru) | Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece | |
CA2118052A1 (en) | N-(Substituted Amino) Pyrrole Derivatives, Preparation Process Thereof, and Herbicidal Compositions | |
HUP0204516A2 (en) | Synergistic fungicidal composition and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |